Polycystic liver disease (PLD) is a group of genetic disorders with limited treatment options and significant morbidity. Hepatic cysts arise from cholangiocytes exhibiting a hyperproliferative phenotype. Considering that hyperproliferation of many cell types is associated with alterations in autophagy, we hypothesized that autophagy is altered in PLD cholangiocytes, contributes to hepatic cystogenesis, and might represent a potential therapeutic target. We employed functional pathway cluster analysis and next-generation sequencing, transmission electron microscopy, immunofluorescence confocal microscopy, and western blotting to assess autophagy in human and rodent PLD cholangiocytes. A three-dimensional culture model was used to study the effects of molecular and pharmacologic inhibition of autophagy on hepatic cystogenesis in vitro, and the polycystic kidney disease-specific rat, an animal model of PLD, to study the effects of hydroxychloroquine, a drug that interferes with the autophagy pathway, on disease progression in vivo. Assessment of the transcriptome of PLD cholangiocytes followed by functional pathway cluster analysis revealed that the autophagy-lysosomal pathway is one of the most altered pathways in PLD. Direct evaluation of autophagy in PLD cholangiocytes both in vitro and in vivo showed increased number and size of autophagosomes, lysosomes, and autolysosomes; overexpression of autophagy-related proteins (Atg5, Beclin1, Atg7, and LC3); and enhanced autophagic flux associated with activation of the cAMP-protein kinase A-cAMP response element-binding protein signaling pathway. Molecular and pharmacologic intervention in autophagy with ATG7 small interfering RNA, bafilomycin A 1 , and hydroxychloroquine reduced proliferation of PLD cholangiocytes in vitro and growth of hepatic cysts in three-dimensional cultures. Hydroxychloroquine also efficiently inhibited hepatic cystogenesis in the polycystic kidney disease-specific rat. Conclusion: Autophagy is increased in PLD cholangiocytes, contributes to hepatic cystogenesis, and represents a potential therapeutic target for disease treatment. (HEPATOLOGY 2018;67:1088-1108.
which the autophagosomal cargo is degraded and recycled.
(1) Originally, autophagy was considered a cellular survival mechanism against unfavorable conditions, in particular starvation. But in recent years an important role for autophagy has emerged in various disorders including diseases of the hepatobiliary system. (2) (3) (4) Moreover, autophagy is now considered as a druggable target for a number of pathologies. (5, 6) In this work, we addressed the role of autophagy in polycystic liver disease (PLD), the hepatic manifestation of autosomal dominant and autosomal recessive polycystic kidney diseases (ADPKD and ARPKD, respectively). PLD is characterized by fluid-filled hepatic cysts that arise from cholangiocytes and grow progressively over time as a result of structural and functional disturbances in numerous intracellular processes and signaling pathways. (7, 8) Considering the association of autophagy with rapid cell proliferation, (2) we speculated that autophagy might play an important role in hepatic cystogenesis, a condition of benign cholangiocyte hyperproliferation.
To our knowledge, studies that implicate autophagy in PLD associated with PKD are limited to a single published work reporting that aberrant activation of the phosphoinositide 3-kinase/mammalian target of rapamycin pathway in the Polycystic Kidney (PCK) rat (an animal model of ARPKD) increased cholangiocyte proliferation and cyst growth, whereas inhibition of this pathway attenuated cholangiocyte proliferation through mechanisms involving apoptosis and/or autophagy. (9) However, a direct contribution of autophagy to hepatic cystogenesis and a role as a potential target for a therapeutic treatment of PLD were not addressed.
Thus, the aims of this work were (1) to directly assess autophagy in human and rodent cholangiocytes of both forms of PLD (i.e., ADPKD and ARPKD), (2) to study a possible contribution of autophagy to hepatic cystogenesis, and (3) to test if autophagy represents a potential therapeutic target for PLD.
Materials and Methods

ANIMALS, CELL CULTURES, AND REAGENTS
Age-matched and sex-matched wild-type (WT; Harlan Sprague Dawley) and PCK rats (Harlan Sprague Dawley background), WT and Pkd2 WS25/-mice, and Pkhd1 del2/del2 mice (all C57BL/6 background) were housed in a 12-hour light/dark cycle and maintained on a standard diet and water ad libitum. After anesthesia (pentobarbital, 50 mg/kg), livers were removed, fixed, and paraffin-embedded. The protocol was approved by the Mayo Institutional Animal Care and Use Committee. Normal (NRC) and PCK rat cholangiocytes as well as normal human (NHC) and ADPKD cholangiocytes were maintained as described. (10) NRC and PCK rat cholangiocytes were stably transfected with microtubule-associated proteins 1A/1B light chain 3 (LC3)-green fluorescent protein (GFP) construct (Invitrogen). ADPKD cholangiocytes were transfected with ATG7 or control small interfering RNAs (siRNAs; Invitrogen). Bafilomycin A 1 and hydroxychloroquine (HCQ) were purchased from Sigma-Aldrich.
RNA PREPARATION AND SEQUENCING
The protocol of cholangiocyte RNA sequencing is described in the Supporting Information.
TRANSMISSION ELECTRON MICROSCOPY
Transmission electron microscopy of liver sections and cultured cholangiocytes was performed as described. (7, 11) 
WESTERN BLOTTING
Proteins were separated by 4%-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and incubated with primary antibodies to Atg5 (SigmaAldrich), Beclin 1 (Novus), Atg7 (Sigma-Aldrich), p62 (Sigma-Aldrich), phosphorylated cAMP response element-binding protein (CREB), CREB (Cell Signaling), and b-actin (Sigma-Aldrich). For LC3 detection, proteins were separated by 4% stacking gels and 20% separating gels, followed by incubation with LC3 antibody (Novus). Corresponding secondary horseradish peroxidase-conjugated antibodies (Santa Cruz Biotechnology) were applied and bands visualized with an enhanced chemiluminescence plus western blotting detection kit (BD Biosciences). Integrated density of protein bands was assessed by ImageJ (National Institutes of Health), and data are presented as arbitrary units compared to b-actin.
IMMUNOFLUORESCENCE CONFOCAL MICROSCOPY
Livers from WT and PCK rats, healthy humans, and patients with ADPKD and ARPKD (provided by the Mayo Clinical Core) were incubated with primary antibodies to Atg5, Atg7, Beclin 1, LC3, and proliferating cell nuclear antigen (PCNA; Santa Cruz) and then with respective secondary fluorescent antibodies (Molecular Probes). Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (Invitrogen). Liver sections and LC3-GFP transfected cultured cholangiocytes were analyzed by a Zeiss LSM-510 microscope (Carl Zeiss, Thornwood, NY). Fluorescence intensity (arbitrary units) of protein staining was assessed by Adobe Photoshop Elements 10 and expressed as percentage change in cystic cholangiocytes compared to respective controls in which fluorescence intensity was considered to equal 100%. The number of LC3-GFP positive puncta was assessed by ImageJ.
CHOLANGIOCYTE PROLIFERATION
Cholangiocyte proliferation was determined by the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI). Cholangiocytes (2,500 cells/well) were grown in regular Dulbecco's modified Eagle's medium/F12 medium at 378C (5% CO 2 and 100% humidity) for 48 hours and treated with bafilomycin A 1 and HCQ (both 100 nM) for an additional 24 hours. Alterations in the proliferation of cultured cholangiocytes after treatment were expressed as a percentage change compared to untreated cholangiocytes in which cell proliferation was considered to equal 100%. Proliferation of PLD cholangiocytes in vivo was evaluated by the number of PCNA-positive nuclei, as described. (12) cAMP MEASUREMENTS Cholangiocytes (10,000/well) were incubated with pasireotide (20 lM), HCQ (100 nM), or both drugs in combination for 15-30 minutes; and cAMP levels were detected using the cAMP-Screen System (Applied Biosystems).
INTRAHEPATIC BILE DUCTS AND CHOLANGIOIDS IN THREE-DIMENSIONAL CULTURES
Microdissected from the PCK rat, liver intrahepatic cystic bile ducts were grown in three-dimensional matrices as described. (7, 11) The cysts were treated with bafilomycin A1 and HCQ (both 100 nM) daily. Images were taken at day 1 (i.e., 24 hours after seeding) and at day 5. The circumference of each cyst was measured using ImageJ software as described. (11) Cholangioids were generated by plating 6,000 human ADPKD cholangiocytes on poly(2-hydroxyethyl methacrylate)-coated surfaces as described. (13) The circumference of cholangioids was measured by Image J and expressed as a percentage change in ATG7 siRNA-transfected cholangioids compared to cholangioids transfected with scrambled controls (in which circumference was considered to equal 100%).
TREATMENT PROTOCOL
PCK rats (4-6 weeks old, n 5 16 female, n 5 16 male) were divided into four groups: (1) pasireotidetreated (n 5 4 female, n 5 4 male), (2) HCQ-treated (n 5 4 female, n 5 4 male), (3) pasireotide 1 HCQtreated (n 5 4 female, n 5 4 male), and (4) untreated (n 5 4 female, n 5 4 male). Pasireotide (20 mg/kg/ day) was dissolved in sterile water and administered through osmotic minipumps (model 2002; Alzet Osmotic Pumps, Cupertino, CA) implanted subcutaneously on the animal back as described. (10) Pumps were replaced every 2 weeks; at this time pasireotide concentrations were adjusted to the animal weight. HCQ (15 mg/kg body weight) was dissolved in dimethyl sulfoxide and injected intraperitoneally; doses of HCQ were adjusted to the rat weight every other week. The untreated group had implanted pumps filled with sterile water and received equal doses of dimethyl sulfoxide (intraperitoneal injections). Rats were sacrificed after 6 weeks of treatment, and body and organ weights were assessed. Cystic and fibrotic areas of liver and kidneys were analyzed as described. (10) Based on our previous experience that the percentage of liver parenchyma occupied by hepatic cysts does not differ between male and female PCK rats, (10, 12, 14) they were combined for estimation of cystic and fibrotic areas.
STATISTICAL ANALYSIS
The data are expressed as the mean 6 SD. Statistical analysis was performed by Student t test, and results were considered statistically significant at P < 0.05.
Results
PLD CHOLANGIOCYTES ARE CHARACTERIZED BY THE ALTERED AUTOPHAGY-LYSOSOMAL PATHWAY
Transcriptome profiling of NRC, PCK rat cholangiocytes, NHC, and human ADPKD cholangiocytes revealed 1,803 genes differentially expressed in PCK rat cholangiocytes and 2,590 genes differentially expressed in human ADPKD cholangiocytes compared to NRC and NHC, respectively. Pathway cluster analysis of these genes by the Kyoto Encyclopedia of Genes and Genomes pathways indicated 33 altered pathways in PCK rat cholangiocytes and 30 pathways in human ADPKD cholangiocytes, including the autophagy-lysosomal pathway that was the most altered pathway in the PCK rat (Fig. 1A) and the second most altered pathway in human ADPKD (Fig.  1B) cholangiocytes.
We also identified 26 genes associated with autophagy in rat cholangiocytes and 34 genes in human cholangiocytes. The majority of these genes were upregulated in PCK rat cholangiocytes (i.e., 19 genes out of 26 genes [ Fig. 1C] ) and in human ADPKD cholangiocytes (i.e., 23 genes out of 34 genes [ Fig. 1D] ). In particular, autophagy-related Atg/ATG (i.e., Atg2/ ATG2, Atg3/ATG3, Atg4/ATG4, Atg5/ATG5, Becn1/ BECN1, Atg7/ATG7, Map1Lc3/MAP1LC3, Agt12/ ATG12, Atg14/ATG14, Atg16l2/ATG16L2, Wipi1/ WIPI1, and Wdr45/WDR45) and genes encoding proteins essential for induction of autophagy (i.e., Ulk1/ ULK1, Ulk2/ULK2, and Rb1cc1/RB1CC1) and for autophagic flux (i.e., Gabarapl1/GABARAPL1) were up-regulated in both rat and human PLD cholangiocytes.
THE NUMBER AND SIZE OF ORGANELLES INVOLVED IN AUTOPHAGY ARE INCREASED IN PLD CHOLANGIOCYTES
The number of autophagosomes, lysosomes, and autolysosomes, the key intracellular organelles involved in autophagy ( Fig. 2A) , was 2-3 times greater in cultured PCK rat and human ADPKD cholangiocytes compared to respective controls (Fig. 2B,C) . PCK rat cholangiocytes contained per section 3.9 6 1.1 autophagosomes, 2.7 6 1.5 lysosomes, and 7.5 6 3.9 autolysosomes compared, correspondingly, to 1.2 6 1.1 autophagosomes, 1.2 6 0.4 lysosomes, and 4.1 6 1.9 autolysosomes in NRC (Fig. 2B,C) . Human ADPKD cholangiocytes contained per section 3.9 6 1.9 autophagosomes, 2.1 6 1.1 lysosomes, and 6.4 6 2.0 autolysosomes compared to 1.8 6 0.8 autophagosomes, 1.0 6 0.8 lysosomes, and 2.1 6 1.4 autolysosomes in NHC (Fig. 2B,C) .
Autophagosomes, lysosomes, and autolysosomes were also larger in PCK rat and human ADPKD cholangiocytes. In PCK cholangiocytes, the circumference of autophagosomes, lysosomes, and autolysosomes was, respectively, 1.53 6 0.30 lm, 0.83 6 0.22 lm, and 4.39 6 1.60 lm compared to 0.78 6 0.06 lm (autophagosomes), 0.29 6 0.14 lm (lysosomes), and 1.76 6 0.28 lm (autolysosomes) in NRC (Fig. 2B,C) . Similarly, in ADPKD cholangiocytes the circumference of autophagosomes, lysosomes, and autolysosomes was, respectively, 1.52 6 0.29 lm, 1.36 6 0.53 lm, and 4.43 6 0.91 lm compared to 0.84 6 0.27 lm (autophagosomes), 0.57 6 0.14 lm (lysosomes), and 1.98 6 0.44 lm (autolysosomes) in NHC (Fig. 2B,C) .
Increased number and size of these organelles were also observed in vivo. Cholangiocytes of PCK rats contained per section 4.3 6 0.9 autophagosomes versus 1.3 6 0.5 in WT rat, 3.5 6 0.8 lysosomes versus 1.6 6 0.4 in WT rat, and 5.8 6 1.2 autolysosomes versus 1.9 6 1.1 in WT rat (Fig. 2D,E) . The circumference of autophagosomes, lysosomes, and autolysosomes was, respectively, 2.96 6 0.73 lm, 1.76 6 0.54 Changes in gene expression in PCK rat and human ADPKD cholangiocytes compared to NRC and NHC (n 5 3 for each experimental conditions) were calculated using R package edgeR. False discovery rate 5 0.05, and log 2 fold change 1 or log 2 fold change -1 were considered as the cutoffs for upregulated and down-regulated genes. Abbreviations: ECM, extracellular matrix; Jak-STAT, Janus kinase-signal transducer and activator of transcription; MAPK, mitogen-activated protein kinase; NOD, nonobese diabetic; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; TGF, transforming growth factor. lm, and 9.38 6 2.38 lm compared to 1.98 6 0.17 lm (autophagosomes), 0.75 6 0.14 lm (lysosomes), and 3.62 6 0.91 lm (autolysosomes) in WT rat (Fig.  2D,E) . Comparable changes in the number and size of autophagic organelles were also observed in cholangiocytes of ADPKD patients (Supporting Fig. S1 ) and Pkd2 WS25/-mouse (an animal model of ADPKD) (Supporting Fig. S2 ).
EXPRESSION OF AUTOPHAGY-RELATED PROTEINS IS INCREASED IN PLD CHOLANGIOCYTES
Expression of selected Atg proteins (i.e., Atg5, Beclin 1, Atg7, and LC3) in livers of PCK rats and humans with ADPKD and ARPKD was increased 2-fold to 3-fold compared to respective controls (Fig. 3A,B) . Similar expression of these proteins was also observed in cholangiocytes of Pkd2 WS25/-mice (an animal model of ADPKD) (Supporting Fig. S3 ). In cultured PCK rat and human ADPKD cholangiocytes, copy numbers of autophagy-related protein transcripts (i.e., Atg5, Beclin 1, Atg7, and LC3; Fig. 3C ) and expression of Atg proteins (Fig. 3D ,E) were 2-fold to 5-fold greater compared to corresponding controls.
AUTOPHAGIC FLUX IS INCREASED IN PLD CHOLANGIOCYTES
Expression of the autophagy marker LC3-II in PCK rat cholangiocytes was greater than in NRC (Fig.  4A,B) and further increased in the presence of bafilomycin A 1 , a drug that inhibits the final steps of autophagy (i.e., prevents autophagosome-lysosome fusion and degradation; Fig. 4A,B) , indicating increased autophagic flux (i.e., the entire process of autophagy).
Expression of the autophagy receptor p62 (the level of which is decreased when autophagic flux is increased (15) ) was reduced in PCK rat cholangiocytes compared to NRC (Fig. 4C,D) . Levels of p62 were partially recovered in PCK rat cholangiocytes in the presence of bafilomycin A 1 (Fig. 4C,D) , also indicating increased autophagic flux.
An increase in autophagic flux in PLD cholangiocytes was also confirmed in cholangiocytes stably transfected with LC3-GFP construct (Fig. 4E,F) . The number of LC3-GFP-positive puncta was greater in PCK rat cholangiocytes compared to NRC. A substantial increase in the number of LC3-GFP puncta in PCK rat cholangiocytes treated with bafilomycin A 1 further indicated increased autophagy.
cAMP SIGNALING CONTRIBUTES TO INCREASED AUTOPHAGY IN PLD CHOLANGIOCYTES
Our bioinformatics analysis revealed that Atg/ATG genes (Atg5/ATG5, Atg7/ATG7, and Map1lc3/ MAP1LC3) in rat and human cholangiocytes harbor CREB binding sites within their promoters, suggesting that overexpression of Atg proteins and increased autophagic flux in PLD cholangiocytes might be associated with the cAMP-protein kinase A (PKA)-CREB signaling pathway. This hypothesis is supported by three sets of our data. First, we demonstrated that in human ADPKD cholangiocytes treated with an activator of PKA, N6-phenyladenosine (6-Phe) cAMP, phosphorylation of CREB (Fig. 5A ) and the level of LC3 and autophagic flux (Fig. 5B) were increased. The effects of 6-Phe-cAMP on autophagy were CREB-mediated because they were abolished by pretreatment of cholangiocytes with the CREB inhibitor 666-15 (Fig. 5B) . Second, expression of Atg5, Atg7, and LC3 in cholangiocytes of PCK rats treated with the somatostatin analogue pasireotide, which lowers cAMP levels, (10) was decreased (Fig. 5C ). Third, treatment of cultured human ADPKD cholangiocytes with pasireotide resulted in decreased expression of Atg5 and Atg7 (Fig. 5D ) and decreased autophagic flux (Fig. 5E) . The inhibitory effects of pasireotide on Atg5 and Atg7 expression were similar to the effects of the CREB inhibitor 666-15 (Fig. 5D) . 
PHARMACOLOGIC INHIBITION OF AUTOPHAGY REDUCED CHOLANGIOCYTE PROLIFERATION AND HEPATIC CYST GROWTH IN VITRO
PLD cholangiocytes exhibit enhanced proliferative capacity determining hepatic cyst growth. (10, 12) Treatment of PCK rat cholangiocytes with the inhibitors of autophagic flux bafilomycin A 1 and HCQ reduced their proliferation by 50% and 32%, respectively (Fig. 6A) . Also, whereas bile ducts isolated from PCK rats expanded in size over time in three-dimensional culture by 75% (Fig. 6B,C) , in the presence of bafilomycin A 1 and HCQ, circumferences of cystic bile ducts were increased at day 5 compared to day 1 only by 34% and 25%, respectively (Fig. 6B,C) , indicating that autophagy inhibitors attenuated cyst growth in vitro.
INHIBITION OF ATG7 EXPRESSION REDUCED FORMATION OF HUMAN ADPKD CHOLANGIOIDS IN THREE-DIMENSIONAL CULTURE
Transfection of human ADPKD cholangiocytes with ATG7 siRNA reduced expression of Atg7 by 75% (B) Levels of cAMP were decreased in PCK rat and human ADPKD cholangiocytes in response to pasireotide (20 micromoles) and HCQ (100 nM) alone. The combination of these two drugs resulted in a greater inhibition of cAMP production. (C) Proliferation of both PCK rat and human ADPKD cholangiocytes was inhibited by pasireotide (20 micromoles) and HCQ (100 nM) alone. The combination of these two drugs resulted in a greater inhibition of cholangiocyte proliferation. All data are presented as mean 6 SD. Abbreviations: PAS, pasireotide; Un-tr, un-treated. (Fig. 6D ) and resulted in a decrease of circumference of cholangioids in three-dimensional culture by 45% (Fig. 6E) , demonstrating the important role of autophagy in cyst formation.
HCQ INHIBITS HEPATIC CYST GROWTH IN PCK RATS
To directly address a potential therapeutic application of our in vitro findings, we treated PCK rats with HCQ and found a significant improvement of disease. Liver weights were decreased in male and female rats by 12.9% and 15.2%, respectively (Supporting Table  S1 ). The hepatic cystic and fibrotic areas were decreased in response to treatment from 16.6 6 1.4% to 12.3 6 1.1% and from 10.4 6 0.8% to 6.4 6 0.8%, correspondingly ( Fig. 7A,B ; Supporting Table S1 ).
The beneficial effects of HCQ were also seen in kidneys of PCK rats. Kidney weights were decreased in both male and female rats by 10.1%, and the renal cystic and fibrotic areas were decreased from 36.7 6 3.4% to 28.9 6 3.5% and from 3.0 6 0.3% to 1.9 6 0.1%, respectively (Supporting Fig. S4 and Table S1 ).
The therapeutic effects of HCQ on hepatic cystogenesis in PCK rats were similar to effects of the somatostatin analogues octreotide and pasireotide, the only known drugs that are currently used for the treatment of PLD (10, 16) (Fig. 7A,B ; Supporting Table S1 ). Importantly, the efficacy of HCQ and pasireotide administered concurrently was enhanced as reflected by a reduction of liver weight in male and female rats by 19.7% and 20.7%, respectively. The hepatic cystic and fibrotic areas were decreased in livers of both male and female rats from 16.6 6 1.4% to 9.1 6 1.6% and from 10.4 6 0.8% to 5.4 6 0.6%, respectively ( Fig.  7A,B ; Supporting Table S1 ). Synergistic therapeutic effects of HCQ and pasireotide were also seen in PCK rat kidneys (Supporting Fig. S4 and Table S1 ).
After treatment of PCK rats with either HCQ alone or pasireotide alone, the number of PCNA-positive nuclei in cholangiocytes was decreased, respectively, by 1.8-fold and 2.3-fold. The drug combination reduced the number of PCNA-positive nuclei by 5.1-fold (Fig. 7C,D) .
Serum biochemical markers relevant to the functions of the hepatobiliary system were comparable in untreated and drug-treated PCK rats (Supporting Table S2 ). This is consistent with our previous works demonstrating that liver function tests remain unchanged in response to treatment with different drugs. (10, 12, 17) Presumably, one of the major reasons for this observation is the short (i.e., 6 weeks) duration of treatment.
HCQ DECREASES THE LEVELS OF cAMP AND PCK RAT CHOLANGIOCYTE PROLIFERATION
Consistent with our previous reports, (10, 12, 17) cAMP levels were increased in rat and human PLD cholangiocytes compared to healthy controls (Fig. 8A) . HCQ alone, pasireotide alone, and the combination of these two drugs reduced cAMP levels, respectively, by 25.6%, 31.0%, and 43.3% in PCK rat cholangiocytes and by 24.9%, 26.9%, and 36.9% in human ADPKD cholangiocytes (Fig. 8B) . HCQ alone and pasireotide alone decreased proliferation of PCK rat cholangiocytes by 33%-42% and human ADPKD cholangiocytes by 28%-35% (Fig. 8C ). Two drugs together had a synergistic effect, decreasing proliferation of PCK rat and human ADPKD cholangiocytes by 61% and 67%, respectively (Fig. 8C) . Thus, these data demonstrate that the therapeutic effects of HCQ on hepatic cystogenesis are presumably associated with inhibition of cAMP levels and cholangiocyte proliferation.
Discussion
The key findings of this study relate to the pathophysiological role of increased cholangiocyte autophagy in PLD. We found that in human and rodent PLD cholangiocytes (1) the autophagy-lysosomal pathway is altered; (2) Atg transcripts and transcripts essential for induction of autophagy are up-regulated; (3) the number and size of autophagosomes, lysosomes, and autolysosomes are increased; (4) selected Atg proteins are overexpressed; (5) autophagic flux is increased; (6) the cAMP-PKA-CREB signaling pathway contributes to increased autophagy; (7) intervention in autophagy with ATG7 siRNA and inhibitors of autophagic flux, bafilomycin A 1 , and HCQ reduces PLD cholangiocyte proliferation and hepatic cyst growth in vitro; (8) HCQ improves disease progression in the PCK rat, an animal model of PLD; and (9) concurrently HCQ and a somatostatin analogue, pasireotide, reduce hepatorenal cystogenesis in the PCK rat more effectively than each drug alone by decreasing cAMP levels and cholangiocyte proliferation to a greater extent than either single drug.
As mentioned, the potential involvement of autophagy in hepatic cystogenesis has been proposed, (9) and the importance of autophagy for PKD also has been suggested. (18) It has been hypothesized that PKD represents a case of suppressed autophagy because the mammalian target of rapamycin pathway, a cellular suppressor of autophagy, is activated in renal cystic epithelial cells. (18) Indeed, in zebrafish and mouse models of ADPKD, rapamycin (an inhibitor of the mammalian target of rapamycin pathway and an inducer of autophagy) showed positive effects on autophagy in renal epithelial cells. (18, 19) It has been also reported, in agreement with our observations presented in this study, that the number of autophagosomes and the expression of autophagy-related proteins (i.e., Beclin 1 and LC3-II) were increased in cystic renal epithelia of two animal models of PKD: Han:SPRD rats and cpk mice. (20) Thus, the experimental evidence on the role of autophagy in PKD remains limited and controversial.
Our work demonstrates that autophagy is increased in human and rodent PLD cholangiocytes by mechanisms most probably associated with aberrant cAMP signaling and contributes to hepatic cystogenesis. Perhaps most importantly, our work demonstrates that when autophagy is targeted either molecularly or pharmacologically, hepatic cyst growth both in vitro and in vivo is reduced. Moreover, pharmacological targeting of autophagy in an animal model of ARPKD, the PCK rat, is also beneficial for cyst growth in the kidney.
In PLD, hepatic cysts derive from cholangiocytes and grow progressively over time, with the involvement of multiple mechanisms tightly associated with the activated cAMP signaling pathway. (7, 8, (10) (11) (12) Taking into account the important role of this signaling pathway in the regulation of autophagy in different cell types, (21, 22) we think that an elevated level of cAMP is the major inducer of autophagy in PLD cholangiocytes and that mechanisms accounting for increased autophagy in PLD cholangiocytes are associated, at least in part, with the cAMP-PKA-CREB signaling pathway.
Recent studies suggest that cAMP signaling influences autophagy negatively or positively depending on the cell type. (21, 23) For example, increased levels of cAMP activate PKA, which in turn phosphorylates a nuclear transcription factor, CREB; and activated CREB influences autophagy through expression of autophagy-related genes. (24, 25) In particular, in hepatocytes, CREB promotes autophagy under nutrient-deprived conditions through up-regulation of autophagy genes Atg7, Ulk1, and Tfeb. (25) Relevant to the possibility that altered autophagy in PLD cholangiocytes is associated with the cAMP-PKA-CREB signaling pathways are four sets of our data. First, in silico bioinformatics analysis revealed that Atg5/ATG5, Becn1/BECN1, Atg7/ATG7, and Map1lc3/MAP1LC3 harbor the CREB binding sites within their promoters. Second, activation of PKA resulted in an increase in CREB phosphorylation and in autophagic flux in human ADPKD cholangiocytes in culture. Third, expression of Atg5 and Atg7 was reduced in cholangiocytes of PCK rats and in cultured human ADPKD cholangiocytes treated with the somatostatin analogue pasireotide, which inhibits the cAMP signaling pathway. Finally, expression of Atg5 and Atg7 was reduced in human ADPKD cholangiocytes treated with a CREB inhibitor, 666-15.
Recently, we demonstrated that a cAMP-linked bile acid receptor, TGR5, contributes to PLD progression (14) and could be considered one of the major inducers of increased cAMP levels in PLD cholangiocytes and potentially in cAMP-regulated autophagy. Given the importance of TGR5 activation and cAMP signaling in other chronic cholestatic conditions, (26) it is likely that TGR5-cAMP-dependent activation of autophagy may also occur in other liver diseases.
A functional outcome of increased autophagy in PLD is elevated proliferation of cholangiocytes and accelerated hepatic cyst growth. The involvement of autophagy in cell proliferation is known, especially in cancer; however, the exact mechanisms of autophagydependent cell proliferation remain poorly understood. (27) Autophagy can both restrain and promote cell proliferation in a context-dependent manner (i.e., depending on the cell type, disease stage, expression of Atg proteins, and other conditions). (27) For example, Atg5 is essential for T-cell proliferation in mice, (28) and Beclin1 and Atg7 are essential for stem-cell proliferation in Caenorhabditis elegans. (29) Our data showing overexpression of Atg5 and Atg7 in hyperproliferative rodent and human PLD cholangiocytes are in agreement with these observations. Manipulation with autophagy in in vitro and in vivo models of PLD demonstrates strong therapeutic effects. Bafilomycin A 1 and HCQ both reduce PLD cholangiocyte proliferation and hepatic cyst growth in three-dimensional culture, and treatment of PCK rats with HCQ reduced hepatic and renal cystogenesis to the same extent as the somatostatin analogues octreotide and pasireotide, the only drugs used in clinical practice for the treatment of PLD. (10, 16) Unfortunately, chronic treatment of PLD patients with somatostatin analogues is costly ($7,000-$11,000 per month). Thus, a search for new therapeutic options for PLD remains of great importance. Our data suggest that inhibition of autophagy in PLD cholangiocytes by HCQ, which is an inexpensive Food and Drug Administrationapproved drug, might be beneficial for PLD patients. We also found that concurrently HCQ and pasireotide reduce hepatorenal cystogenesis in PCK rats more effectively than each drug alone. The mechanisms of the synergistic effects of these two drugs remain unclear. It has been demonstrated in in vitro and in vivo studies on the rat inner medullary collecting ducts that chloroquine inhibits both basal and arginine vasopressin-induced cAMP production. (30, 31) Our data show a greater reduction in cholangiocyte cAMP levels when the drugs are used together than when they are used alone. Thus, it appears that both drugs, through different mechanisms, affect cAMP signaling.
In summary, our study provides direct evidence that autophagy is increased in PLD cholangiocytes, contributes to hepatic cystogenesis, and should be considered a therapeutic target for the treatment of liver disorders associated with ADPKD and ARPKD.
